Resonance Health Ltd (ASX:RHT) Share Price

Company Profile

Business description
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Contact
141-143 Burswood Road
Level 1
Burswood
PerthWA6100
AUS
T: +61 892865300
https://www.resonancehealth.com
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2025
Employees
18

Recommended

Current operating conditions are challenging but over the long-term prospects are better.

Johannes Faul | 25 February 2025

Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.

Joseph Taylor | 25 February 2025

Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.

Morningstar | 25 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,477.30	20.70	-0.24%
CAC 40	8,137.26	86.19	1.07%
DAX 40	22,732.24	321.97	1.44%
Dow JONES (US)	43,758.96	137.80	0.32%
FTSE 100	8,722.03	53.36	0.62%
HKSE	23,787.93	753.91	3.27%
NASDAQ	19,196.80	170.41	0.90%
Nikkei 225	38,142.37	95.42	-0.25%
NZX 50 Index	12,452.46	145.19	1.18%
S&P 500	5,991.45	36.20	0.61%
S&P/ASX 200	8,240.70	11.20	-0.14%
SSE Composite Index	3,380.21	34.17	1.02%